Dr. Zhang Bo-li is an academician and a China-renowned specialist and academic leader in Chinese internal medicine,a national key discipline(recognized as important and receiving support by the Chinese government). He is currently the President of the Tianjin University of Traditional ChineseMedicine and the China Academy of Chinese Medical Sciences. He is also the Deputy ChiefEngineer of the National Major Scientific and Technological Special Project for "Significant New Drugs Development",a member of the Medical Reform Advisory Committee of the State Council, Vice Committee Director of the Pharmacopoeia Committee, Director of the National Chinese MedicineTeaching Advisory Board of the Ministry of Education and Director of the Educational Instruction Committee of the World Federation of Chinese Medicine Societies. Moreover, he holds concurrent posts such as Honorary President of the China Association of Integrative Medicine, Vice President of the China Association of Traditional Chinese Medicine and Vice President of the World Federation of Chinese Medicine Societies.

For decades, Dr. Zhang has been devoted to the prevention and treatment of cardiovascular and cerebrovascular diseases by integrating traditional Chinese medicine with western medicine, and to the modernization of Chinese medicine(CM). He carried out studies on vascular dementia(VD) and formulated the classification criteriafor VD patterns and a treatment scheme based on three phases,i.e., stable, fluctuating and aggravated phases. He specified the patterns and manifestations of stroke as well as the dynamic progression of its premonitory symptoms, and developed a comprehensive therapeutic schedule. He created the pharmacological method of cerebrospinal fluid(CSF) and demonstrated the protective effect of Chinese medicinals on nerve cells and the relevant mechanisms. He completed the first large-scale evidence-based study on the secondary prevention of coronary heart disease with Chinese medicinals, and developed a series of methods for evidence-based evaluation on CM. He served as Chief Scientist of the National Program on Key Basic Research Project of China (973 Program) for three consecutive terms and developed the theory of effect-based compatibility as well as the critical technology for the research and development of modern Chinese medicinals through component-based compatibility. He expanded the research field of the secondary development of Chinese patent medicine which introduced a large group of mass market medicines, and initiated the inteligent manufacturing of Chinese medicinals which promoted the technological upgrading of CM industry.

Dr. Zhang has won 7 national awards(including the first prize for national progress in science and technology) and 10 first-prize provincial and ministerial awards for progress in science and technology. He has published more than 350 papers and over 30monographs or textbooks. He has mentored and cultivated more than 200 postgraduates.

Dr. Zhang is widely recognized for his prominent contributions inadvancing CM. Since 1991, he has been granted a special government allowance by the State Council. He has been conferred with many honorary titles and awards, including National Advanced Worker(2005), Outstanding Scientific and Technological Worker (2001)and National Young and Middle-aged Expert with Outstanding Contribution(1991) as well as the Ho Leung Ho Lee Prize (2006), Wu Jie-ping Medical Research Award (2015) and International Award for Outstanding Contribution to Chinese Medicine(2010).

主编 钟赣生 陈蔚文 赵中振（中国香港）

Chief Editors  Zhong Gan-sheng Chen Wei-wen Zhao Zhong-zhen（Hong Kong，China）

副主编 白效龙（美国） 约翰·斯科特（美国） 金华 唐德才

周祯祥

Associate Chief Editors  Eric Brand（USA）John Scott（USA）Jin Hua Tang De-cai Zhou Zhen-xiang CbhN2es2toHxGqygih4cMmTC3OZG/MnT5fqev5Fzm9K3sWHt50Mr0Su1MndaFueN